Premastectomy Radiotherapy and Immediate Breast Reconstruction: A Randomized Clinical Trial

• Published in: JAMA network open Vol. 7; no. 4; p. e245217
• Main Authors: Schaverien, Mark V, Singh, Puneet, Smith, Benjamin D, Qiao, Wei, Akay, Catherine L, Bloom, Elizabeth S, Chavez-MacGregor, Mariana, Chu, Carrie K, Clemens, Mark W, Colen, Jessica S, Ehlers, Richard A, Hwang, Rosa F, Joyner, Melissa M, Largo, Rene D, Mericli, Alexander F, Mitchell, Melissa P, Shuck, John W, Tamirisa, Nina, Tripathy, Debasish, Villa, Mark T, Woodward, Wendy A, Zacharia, Rensi, Kuerer, Henry M, Hoffman, Karen E
• Format: Journal Article
• Language: English
• Published: United States American Medical Association 01.04.2024
• Subjects: Online Only; Original Investigation; Surgery
• DOI: 10.1001/jamanetworkopen.2024.5217
• ISSN: 2574-3805

Premastectomy radiotherapy (PreMRT) is a new treatment sequence to avoid the adverse effects of radiotherapy on the final breast reconstruction while achieving the benefits of immediate breast reconstruction (IMBR). To evaluate outcomes among patients who received PreMRT and regional nodal irradiation (RNI) followed by mastectomy and IMBR. This was a phase 2 single-center randomized clinical trial conducted between August 3, 2018, and August 2, 2022, evaluating the feasibility and safety of PreMRT and RNI (including internal mammary lymph nodes). Patients with cT0-T3, N0-N3b breast cancer and a recommendation for radiotherapy were eligible. This trial evaluated outcomes after PreMRT followed by mastectomy and IMBR. Patients were randomized to receive either hypofractionated (40.05 Gy/15 fractions) or conventionally fractionated (50 Gy/25 fractions) RNI. The primary outcome was reconstructive failure, defined as complete autologous flap loss. Demographic, treatment, and outcomes data were collected, and associations between multiple variables and outcomes were evaluated. Analysis was performed on an intent-to-treat basis. Fifty patients were enrolled. Among 49 evaluable patients, the median age was 48 years (range, 31-72 years), and 46 patients (94%) received neoadjuvant systemic therapy. Twenty-five patients received 50 Gy in 25 fractions to the breast and 45 Gy in 25 fractions to regional nodes, and 24 patients received 40.05 Gy in 15 fractions to the breast and 37.5 Gy in 15 fractions to regional nodes, including internal mammary lymph nodes. Forty-eight patients underwent mastectomy with IMBR, at a median of 23 days (IQR, 20-28.5 days) after radiotherapy. Forty-one patients had microvascular autologous flap reconstruction, 5 underwent latissimus dorsi pedicled flap reconstruction, and 2 had tissue expander placement. There were no complete autologous flap losses, and 1 patient underwent tissue expander explantation. Eight of 48 patients (17%) had mastectomy skin flap necrosis of the treated breast, of whom 1 underwent reoperation. During follow-up (median, 29.7 months [range, 10.1-65.2 months]), there were no locoregional recurrences or distant metastasis. This randomized clinical trial found PreMRT and RNI followed by mastectomy and microvascular autologous flap IMBR to be feasible and safe. Based on these results, a larger randomized clinical trial of hypofractionated vs conventionally fractionated PreMRT has been started (NCT05774678). ClinicalTrials.gov Identifier: NCT02912312.